Estimating Effect of Antiviral Drug Use during Pandemic (H1N1) 2009 Outbreak, United States

被引：28

作者：

Atkins, Charisma Y. ^{[1
]}

Patel, Anita ^{[1
]}

Taylor, Thomas H., Jr. ^{[1
]}

Biggerstaff, Matthew ^{[1
]}

Merlin, Toby L. ^{[1
]}

Dulin, Stephanie M. ^{[1
]}

Erickson, Benjamin A. ^{[1
]}

Borse, Rebekah H. ^{[1
]}

Hunkler, Robert ^{[2
]}

Meltzer, Martin I. ^{[1
]}

机构：

[1] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA

[2] IMS Hlth, Fountain Hills, AZ USA

来源：

EMERGING INFECTIOUS DISEASES | 2011年 / 17卷 / 09期

关键词：

NEURAMINIDASE INHIBITOR ZANAMIVIR; INFLUENZA-RELATED COMPLICATIONS; OSELTAMIVIR TREATMENT; EFFICACY; SAFETY; BENEFITS; IMPACT; VIRUS; COST; RISK;

D O I：

10.3201/eid1709.110295

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

From April 2009 through March 2010, during the pandemic (H1N1) 2009 outbreak, approximate to 8.2 million prescriptions for influenza neuraminidase-inhibiting antiviral drugs were filled in the United States. We estimated the number of hospitalizations likely averted due to use of these antiviral medications. After adjusting for prescriptions that were used for prophylaxis and personal stockpiles, as well as for patients who did not complete their drug regimen, we estimated the filled prescriptions prevented approximate to 8,400-12,600 hospitalizations (on the basis of median values). Approximately 60% of these prevented hospitalizations were among adults 18-64 years of age, with the remainder almost equally divided between children 0-17 years of age and adults >= 65 years of age. Public health officials should consider these estimates an indication of success of treating patients during the 2009 pandemic and a warning of the need for renewed planning to cope with the next pandemic.

引用

页码：1591 / 1598

页数：8

共 26 条

[1] Early administration of oral oseltamivir increases the benefits of influenza treatment [J].